SPHDF (Santhera Pharmaceuticals Holding AG) PB Ratio: (As of Jun. 24, 2026)


SPHDF Santhera Pharmaceuticals Holding AG SPHDF
39 GF Score
Price $23.25
GF Value $24.73
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Santhera Pharmaceuticals Holding AG PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), Santhera Pharmaceuticals Holding AG's share price is $23.25. Santhera Pharmaceuticals Holding AG's Book Value per Share for the quarter that ended in Dec. 2025 was $-1.11. Hence, Santhera Pharmaceuticals Holding AG's PB Ratio of today is .

The historical rank and industry rank for Santhera Pharmaceuticals Holding AG's PB Ratio or its related term are showing as below:

During the past 13 years, Santhera Pharmaceuticals Holding AG's highest PB Ratio was 57.09. The lowest was 1.31. And the median was 4.64.

SPHDF's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.83
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Santhera Pharmaceuticals Holding AG's average Book Value Per Share Growth Rate was -140.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 49.00% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Santhera Pharmaceuticals Holding AG was 100.70% per year. The lowest was -78.30% per year. And the median was -25.50% per year.

Back to Basics: PB Ratio


Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Santhera Pharmaceuticals Holding AG PB Ratio Related Terms


Santhera Pharmaceuticals Holding AG PB Ratio Historical Data

* Premium members only.

The historical data trend for Santhera Pharmaceuticals Holding AG's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG PB Ratio Chart

Santhera Pharmaceuticals Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.45 0.00 1.91 3.88 0.00

Santhera Pharmaceuticals Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.91 2.55 3.88 0.00 0.00

SPHDF vs VRTX, REGN, ALNY: PB Ratio Comparison

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santhera Pharmaceuticals Holding AG PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's PB Ratio distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's PB Ratio falls into.


SPHDF
39GF Score
Santhera Pharmaceuticals Holding AG SPHDF
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santhera Pharmaceuticals Holding AG PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Santhera Pharmaceuticals Holding AG's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=23.25/-1.107
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?

Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued. The current stock price of $23.25 is trading 6% below its estimated GF Value™ of $24.73. GuruFocus considers Santhera Pharmaceuticals Holding AG to be Fairly Valued.

Key valuation signals for SPHDF:

  • PB Ratio:
  • GF Value™: $24.73 vs. price of $23.25 (6% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Santhera Pharmaceuticals Holding AG Business Description

Address Hohenrainstrasse 24, Pratteln, CHE, 4133
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score

Get the complete analysis for SPHDF

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.25
Price
$24.73
GF Value